Pelareorep for treating metastatic malignant melanoma after previous therapy [ID941]
In development [GID-TA10686] Expected publication date: TBC
Search results
573 results
-
-
Pelareorep for treating relapsed or refractory multiple myeloma [ID1028]
In development [GID-TA10687] Expected publication date: TBC
-
Nintedanib for treating interstitial lung disease caused by systemic sclerosis [ID1420]
In development [GID-TA10427] Expected publication date: TBC
-
Tebentafusp for treating metastatic HLA-A*02:01 positive uveal melanoma (ID1441)
In development [GID-TA10428] Expected publication date: 04 May 2022
-
Atezolizumab monotherapy for untreated PD-L1 positive metastatic non-small-cell lung cancer [ID1678]
In development [GID-TA10587] Expected publication date: 02 June 2021
-
Nivolumab with cabozantinib for untreated advanced or metastatic renal cell carcinoma [ID1625]
In development [GID-TA10643] Expected publication date: 16 June 2021
-
Crisaborole for treating mild to moderate atopic dermatitis in people aged 2 years and older (ID1195)
In development [GID-TA10435] Expected publication date: TBC
-
Omburtamab for treating relapsed neuroblastoma [ID1664]
In development [GID-TA10608] Expected publication date: TBC
-
Cardiovascular disease: risk assessment and reduction, including lipid modification
In development [GID-NG10178] Expected publication date: 19 April 2023
-
Type 1 diabetes in adults: diagnosis and management (update)
In development [GID-NG10159] Expected publication date: TBC
-
Shared decision making
In development [GID-NG10120] Expected publication date: 17 June 2021
-
Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1332]
In development [GID-TA10272] Expected publication date: 14 July 2021
-
Atezolizumab with cobimetinib and vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma [ID1674]
In development [GID-TA10543] Expected publication date: TBC
-
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma ID1352
In development [GID-TA10319] Expected publication date: TBC
-
Luspatercept for treating anaemia caused by myelodysplastic syndromes [ID1550]
In development [GID-TA10508] Expected publication date: TBC
-
Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]
In development [GID-TA10623] Expected publication date: TBC
-
Nivolumab with ipilimumab for untreated PD-L1 mutation-positive non-small-cell lung cancer [ID1675]
In development [GID-TA10585] Expected publication date: TBC
-
Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer before chemotherapy [ID1619]
In development [GID-TA10490] Expected publication date: TBC
-
Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer after chemotherapy [ID1621]
In development [GID-TA10492] Expected publication date: TBC
-
Pembrolizumab with platinum-based chemotherapy and radiation for treating unresectable locally advanced squamous cell carcinoma of the head and neck [ID1667]
In development [GID-TA10567] Expected publication date: 24 November 2021
-
Nivolumab for treating platinum-resistant advanced or recurrent ovarian cancer [ID2714]
In development [GID-TA10590] Expected publication date: 19 May 2021
-
Liraglutide for managing obesity in people aged 12 to 17 [ID1630]
In development [GID-TA10563] Expected publication date: TBC
-
Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma [ID2709]
In development [GID-TA10579] Expected publication date: TBC
-
KTE-X19 for previously treated B-precursor acute lymphoblastic leukaemia ID1494
In development [GID-TA10424] Expected publication date: TBC
-
Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer [ID1665]
In development [GID-TA10550] Expected publication date: TBC
-
Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 1 systemic therapy [ID1684]
In development [GID-TA10580] Expected publication date: TBC
-
Axicabtagene ciloleucel for treating relapsed or refractory low-grade non-Hodgkin lymphoma [ID1685]
In development [GID-TA10578] Expected publication date: TBC
-
Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly ID1596
In development [GID-TA10497] Expected publication date: TBC
-
Nivolumab with ipilimumab for neoadjuvant treatment of early non-small-cell lung cancer [ID3756]
In development [GID-TA10631] Expected publication date: TBC
-
Listeria monocytogenes vaccine for previously treated malignant pleural mesothelioma ID1353
In development [GID-TA10320] Expected publication date: TBC
-
Tisotumab vedotin for treating recurrent or metastatic cervical cancer after systemic therapy [ID3753]
In development [GID-TA10620] Expected publication date: TBC
-
ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]
In development [GID-TA10489] Expected publication date: TBC
-
Apalutamide for treating non-metastatic, hormone-relapsed prostate cancer [ID1174]
In development [GID-TA10377] Expected publication date: TBC
-
ADI-PEG 20 for previously treated hepatocellular carcinoma [ID1025]
In development [GID-TA10259] Expected publication date: TBC
-
Abemaciclib for treating KRAS mutation-positive non-small-cell lung cancer after platinum-based chemotherapy ID1147
In development [GID-TA10343] Expected publication date: TBC
-
Third molars (impacted) - prophylactic removal [ID898]
In development [GID-TAG525] Expected publication date: TBC
-
Multiple sclerosis - sativex [ID387]
In development [GID-TAG368] Expected publication date: TBC
-
Managing common infections - antimicrobial prescribing guidelines
In development [GID-NG10050] Expected publication date: TBC
-
Skin abscess: antimicrobial prescribing
In development [GID-NG10163] Expected publication date: TBC
-
Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma [ID3775]
In development [GID-TA10636] Expected publication date: TBC
-
Rehabilitation after traumatic injury
In development [GID-NG10105] Expected publication date: 23 November 2021
-
Esketamine for treatment-resistant depression (ID1414)
In development [GID-TA10371] Expected publication date: TBC
-
Chronic pain: assessment and management
In development [GID-NG10069] Expected publication date: TBC
-
Brolucizumab for treating wet age-related macular degeneration [ID1254]
In development [GID-TA10455] Expected publication date: 03 February 2021
-
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 1 prior therapy [ID1557]
In development [GID-TA10485] Expected publication date: 23 June 2021
-
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency [ID3802]
In development [GID-TA10670] Expected publication date: TBC
-
AR101 for treating peanut allergy [ID1282]
In development [GID-TA10713] Expected publication date: TBC
-
Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy [ID1680]
In development [GID-TA10551] Expected publication date: 10 February 2021
-
Pegcetacoplan for previously treated paroxysmal nocturnal haemoglobinuria [ID3746]
In development [GID-TA10651] Expected publication date: 02 February 2022
-
Clostridioides difficile infection: antimicrobial prescribing: draft guidance consultation
We are listening to your views on this antimicrobial prescribing guideline. Comments close 17 February 2021.